› Forums › General Melanoma Community › MK-3475 Approval?
- This topic has 24 replies, 5 voices, and was last updated 9 years, 11 months ago by Cooper.
- Post
- Replies
-
-
- June 23, 2014 at 2:01 pm
Does this source also mention any restrictions, such as prior IPI fail and/or BRAF therapies if BRAF positive?
-
- June 23, 2014 at 2:49 pm
Catherine Poole at MIF has been trying to gather information from her contacts about this and put up a post this morning with some information here:
http://forum.melanomainternational.org/mif/viewtopic.php?f=54&t=35124
-
- June 23, 2014 at 4:20 pm
On a more favorable note — When looking at this report, it looks like patients who are IPI untreated do better that IPI treated patients when given pembrolizumab —–
-
- June 25, 2014 at 11:26 am
Perhaps with all the new test results Merck will allow melanoma patients to take pembrolizumab regardless of having been previously treated with IPI. I know that some patients opted not to take the IPI for other health reasons. Allowing those patients access to pembrolizumab seem like a no brainer based on the current data.
-
- June 25, 2014 at 11:26 am
Perhaps with all the new test results Merck will allow melanoma patients to take pembrolizumab regardless of having been previously treated with IPI. I know that some patients opted not to take the IPI for other health reasons. Allowing those patients access to pembrolizumab seem like a no brainer based on the current data.
-
- June 25, 2014 at 11:26 am
Perhaps with all the new test results Merck will allow melanoma patients to take pembrolizumab regardless of having been previously treated with IPI. I know that some patients opted not to take the IPI for other health reasons. Allowing those patients access to pembrolizumab seem like a no brainer based on the current data.
-
- June 23, 2014 at 4:20 pm
On a more favorable note — When looking at this report, it looks like patients who are IPI untreated do better that IPI treated patients when given pembrolizumab —–
-
- June 23, 2014 at 4:20 pm
On a more favorable note — When looking at this report, it looks like patients who are IPI untreated do better that IPI treated patients when given pembrolizumab —–
-
- June 23, 2014 at 2:49 pm
Catherine Poole at MIF has been trying to gather information from her contacts about this and put up a post this morning with some information here:
http://forum.melanomainternational.org/mif/viewtopic.php?f=54&t=35124
-
- June 23, 2014 at 2:49 pm
Catherine Poole at MIF has been trying to gather information from her contacts about this and put up a post this morning with some information here:
http://forum.melanomainternational.org/mif/viewtopic.php?f=54&t=35124
- You must be logged in to reply to this topic.